Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Advocates claim Gilead and others unfairly limited competition for HIV combination pills.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.
Starting Symtuza quickly after HIV diagnosis is tied to high viral suppression.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
Researchers enrolled participants within 14 days of their HIV diagnosis.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.
Researchers have presented 96-week results from an advanced trial of Symtuza compared with Prezcobix plus Truvada.
Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.
The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.
A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)
An ongoing study is giving the regimen to those acutely infected with HIV, before waiting for results of resistance and other lab tests.
Janssen’s single-tablet antiretroviral regimen was approved on July 17.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.